CD19 CAR-γδ T cell therapy (People'S Liberation Army Air Force Military Medical University)

N/A

Report date: 2026/05/02 20:00:18

Base Information

Drug NameCD19 CAR-γδ T cell therapy (People'S Liberation Army Air Force Military Medical University)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > Chimeric antigen receptor γδT cell therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Gamma delta T-cell therapy > Chimeric antigen receptor γδT cell therapy
Mechanisms of ActionB-lymphocyte antigen CD19 modulatorsT lymphocyte replacements
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsLupus NephritisGlomerulonephritis, MembranousGlomerulonephritis, IGA
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesPeople'S Liberation Army Air Force Military Medical University
China Registration ClassN/A

Develop Information

Active CompaniesPeople'S Liberation Army Air Force Military Medical University
Inactive CompaniesN/A
Active IndicationsLupus NephritisGlomerulonephritis, MembranousGlomerulonephritis, IGA
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A